FDA's Poor On-Time User Fee Performance Weighs On Renewal Debate
Executive Summary
FDA's poor on-time performance in reviewing new drug applications will be an issue as the agency and industry negotiate the outputs expected from the next Prescription Drug User Fee Act reauthorization